« A New Book on the Drug Industry And Its Image |
| The Happiest Darn Drug Company in America »
December 20, 2012
CNS Drug Development Claims Another Victim
Tiny Allon Therapeutics had an ambitious plan to go after progressive supranuclear palsy, a kind of progressive brain deterioration, and thence (they hoped) to other neurodegenerative disorders. The lead compound was davunetide, an oligopeptide derived from activity-dependent neuroprotective protein, ADNP.
It was a reasonable idea, but neurodegeneration is not a reasonable area. The drug has now completely wiped out in the clinic, failing both primary endpoints in its pivotal trial. This is one example of the sort of research that most people don't ever hear about, from a small company that most people will never have heard of at all. But this is the background activity of drug research (with an all-too-common outcome), and if more people were aware of it, perhaps that would be a good thing (see today's other post).
+ TrackBacks (0) | Category: Clinical Trials | The Central Nervous System
POST A COMMENT
- RELATED ENTRIES
- Merck's Aftermath
- Models and Reality
- Rewriting History at the Smithsonian?
- The FDA: Too Loose, Or Appropriately Brave?
- More Magic Methyls, Please
- Totaling Up a Job Search
- Humble Enzyme Dodges Spotlight
- Unraveling An Off-Rate